NEWS

Coulter Partners places Non-Executive Director on the Board of Therachon AG

Coulter Partners was delighted to partner with global biotechnology company, Therachon to secure the appointment of Hans Schikan, Pharm.D., as a non-executive director to the Board of Directors. Therachon focuses on developing treatments for rare, genetic diseases that currently have no available treatments. Their lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism.

Hans Schikan currently serves as Chairman at Asceneuron (Switzerland), Complix (Belgium) and InteRNA (Netherlands), and is a non-executive director at Hansa Medical (Sweden), Swedish Orphan Biovitrum (Sweden), Wilson Therapeutics (Sweden) and Dutch Top Sector Life Sciences & Health (Netherlands). Previously, he was the CEO of Prosensa, which used RNA modulation to treat rare diseases such as Duchenne muscular dystrophy (DMD). While at Prosensa, he oversaw the M&A transaction with BioMarin for up to $840 million. Prior to that, he held senior strategic and commercial positions at Genzyme and Organon. Hans Schikan received his Pharm.D. from the University of Utrecht (Netherlands).

I am delighted to welcome Dr. Schikan to the Board of Directors and thank Coulter Partners for their outstanding work on our behalf,” says Luca Santarelli, M.D., Therachon’s Chief Executive Officer and Director. “Hans’ depth of experience will be invaluable in strengthening our board capabilities and Therachon’s commitment to harnessing new treatments for patients with high unmet medical needs.

 

About Therachon

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. This rare genetic condition affects about one in 25,000 children and is caused by a genetic mutation of the FGFR3 receptor, which stunts child bone growth. Therachon is committed to translating the promise of its science into new treatments for patients with high unmet medical needs. For more information, visit www.therachon.com and follow Therachon on Twitter.